Trial Profile
An International, Multicenter, Randomized, Double-Blind Study of Vorinostat (MK-0683) or Placebo in Combination With Bortezomib in Patients With Multiple Myeloma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs Vorinostat (Primary) ; Bortezomib
- Indications Multiple myeloma
- Focus Registrational; Therapeutic Use
- Acronyms Vantage 088
- Sponsors Merck & Co; Merck Sharp & Dohme
- 19 Jun 2019 This trial has been completed in Czech Republic, according to European Clinical Trials Database.
- 20 Aug 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 07 May 2015 According to the ClinicalTrials.gov record, planned end date changed from 1 Mar 2016 to 1 Mar 2017.